“…Despite this high short‐term morbidity and mortality, a therapeutic gold standard has not been established: There are several studies, including a recent prospective work and a meta‐analysis, as well as case reports on medical, surgical, and interventional approaches without a clear superiority regarding the clinical outcome. Inter alia, there are reports of different types of antiplatelet therapy including aspirin, clopidogrel, and ticlopidine, anticoagulation by either heparin, enoxaparin, dalteparin, or warfarin, off‐label uses of dabigatran or apixaban, surgical thrombectomy, and interventional stent‐retriever maneuvers (Table ). Based on the infrequency of description, none of these studies particularly addresses incidental findings but rather focus on symptomatic patients admitted to hospital for stroke or TIA.…”